Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK233705 in COPD subjects
NCT00376714Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of darotropium bromide in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoints: Adverse events, Blood pressure and 3 more. Started Aug 2006; status: completed.
02
Drugs
darotropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00376714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376714.